Table 3.
Projected lifetime outcomes of lumacaftor/ivacaftor + SC versus SC.
| Projected health outcomes | Base case |
100% persistence |
|||
|---|---|---|---|---|---|
| SC | LUM/IVA+SC | LUM/IVA + SC versus SC | LUM/IVA + SC | LUM/IVA + SC versus SC | |
| Median projected survival, years (95% CI) | 39.4 (38.1, 40.8) | 45.5 (43.5, 47.6) | 6.1 (4.3, 8.2) | 47.2 (44.9, 50.6) | 7.8 (5.7, 11.1) |
| Mean residual life-years (95% CI) | 23.1 (21.8, 24.6) | 30.8 (27.7, 34.0) | 7.8 (4.8, 10.8) | 32.9 (29.2, 36.8) | 9.8 (6.2, 13.6) |
| Mean time in ppFEV1 categories, years | |||||
| ⩾90% | 2.6 | 4.6 | 2.1 | 5.3 | 2.7 |
| 70 to <90% | 5.1 | 8.5 | 3.4 | 9.4 | 4.4 |
| 40 to <70% | 10.5 | 13.8 | 3.3 | 14.7 | 4.2 |
| <40% | 4.9 | 3.9 | −1.0 | 3.5 | −1.5 |
| Patients undergoing lung transplantation, % | 6.2 | 3.2 | −3.0 | 2.8 | −3.4 |
| Average time until lung transplantation, years | 28.0 | 40.1 | 12.1 | 43.5 | 15.5 |
CI, confidence interval; LUM/IVA, lumacaftor/ivacaftor; ppFEV1, percent predicted forced expiratory volume in 1 second; SC, standard care.